Amid a share value slump and executive turmoil, Pfizer reported a robust quarter, thanks in part to Covid-19 drug sales.

Shares of Pfizer (PFE) initially rose slightly after markets reacted to the firm’s quarterly results. By the end of the day yesterday, PFE stock lost 1.39%. Pfizer reported topline growth of $2.8 ...

Pfizer Inc ( (PFE) ) has realeased its Q3 earnings. Here is a breakdown of the information Pfizer Inc presented to its investors. Pfizer Inc., ...

Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the latest C ...

Portfolio manager Dave Wagner stressed the need for further cost management and streamlined operations. With optimistic ...

The CDC has just announced a second shot for elders and the immunocompromised people – but when’s the best time?

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...